Amy M. DeLozier

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Daniel J. Wallace, Richard Furie, Yoshiya Tanaka et al. · The Lancet · 2018 · 513 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials

Eric L. Simpson, J.‐P. Lacour, Lynda Spelman et al. · British Journal of Dermatology · 2020 · 379 citations

Medicine, Dermatology, Pharmacology +13

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Emma Guttman‐Yassky, Jonathan I. Silverberg, Osamu Nemoto et al. · Journal of the American Academy of Dermatology · 2018 · 311 citations

Medicine, Dermatology, Pharmacology +11

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

Kristian Reich, Kenji Kabashima, Ketty Peris et al. · JAMA Dermatology · 2020 · 279 citations · Full text

Medicine, Dermatology, Pharmacology +15

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Eric L. Simpson, Robert Bissonnette, Lawrence F. Eichenfield et al. · Journal of the American Academy of Dermatology · 2020 · 178 citations

Life Sciences, Dermatology, Immunology +11